Refractory Chronic Myelomonocytic Leukemia Clinical Trials

19 clinical trials for Refractory Chronic Myelomonocytic Leukemia across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms — RECRUITING · PHASE1
• CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia — RECRUITING · PHASE1
• A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia — RECRUITING · PHASE2
• Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse — RECRUITING · PHASE1
• Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm — RECRUITING · PHASE1
• Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia — RECRUITING · PHASE1
• CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia — RECRUITING · PHASE1
• A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) — RECRUITING · PHASE1
• Q702 for the Treatment of Patients With Hematologic Malignancies — RECRUITING · PHASE1
• Hu8F4 in Treating Patients With Advanced Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia — TERMINATED · PHASE1
• Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome — TERMINATED · PHASE2
• FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia — TERMINATED · PHASE1
• Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome — COMPLETED · PHASE2
• Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome — COMPLETED · PHASE1
• Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents — COMPLETED · PHASE1
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial — TERMINATED · PHASE1
• A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies — COMPLETED · PHASE1

Refine this search